Sun Pharma receives DCGI approval for generic version of semaglutide injection
Sun Pharmaceutical Industries announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity.
Sun Pharma gets DCGI nod for Wegovy-like weight loss drug, launch after Novo Nordisk’s patent expiry
Sun Pharma has received DCGI approval to launch Noveltreat, a generic semaglutide injection for chronic weight management in India. This GLP-1 receptor agonist will be available after patent expiry, offering a crucial treatment option for India’s growing obesity and diabetes burden. The approval follows successful Indian clinical trials.
Layer-by-Layer Polymeric Films: A Novel Approach to Buccal GLP-1 Delivery
Buccal delivery offers a promising alternative to oral drug administration by enabling direct systemic absorption and avoiding first-pass metabolism. Multilayer polymeric films represent a promising strategy for the sequential delivery of drug and absorption enhancer in the oral cavity. Here, dual- and triple-layer films were fabricated via slot-die coating, incorporating a GLP-1 receptor agonist (GLP-1-RA) […]
Health Canada warns of fake semaglutide drugs, cites ‘product safety’ risks
Health Canada is warning Canadians of the dangers of buying “fake or unauthorized products” meant to replicate popular GLP-1 drugs such as Ozempic, Rybelsus and Wegovy.
Investors load Corxel with $287M for a ‘differentiated’ obesity pill
The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.
Jelly Roll’s wife says weight-loss drug sent her into ‘worst suicidal depression’
This story discusses suicide. If you or someone you know is having thoughts of suicide, please contact the Suicide & Crisis Lifeline at 988 or 1-800-273-TALK (8255). Bunnie XO, the wife of country singer Jelly Roll, is discussing how a weight-loss medication may have led to her experiencing a “dark” depression. During an episode of […]
Is the 2026 Market Rotation Already Underway? Here’s What Could Lead After the Magnificent 7
Quick Read Magnificent Seven stocks are in the red for 2026 as collective momentum has stalled. Eli Lilly partnered with Nvidia on drug discovery as GLP-1 pills show growth potential. Broadcom trades at 33.3x forward P/E with JP Morgan citing custom silicon momentum. Are you ahead, or behind on retirement? SmartAsset’s free tool can match […]
Medifast’s Q4 Guidance Remains Weak: When Does Growth Return?
Medifast, Inc.’s MED guidance for the fourth quarter of 2025 remains weak, with revenue projected to be between $65 million and $80 million and a loss per share ranging from 70 cents to $1.25. This reflects quite a deterioration from revenues of $119 million and adjusted earnings per share of 10 cents recorded in the […]
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool. Date Thursday, Feb. 6, 2025 at 10 a.m. ET Call participants Chair and Chief Executive Officer — David A. Ricks Chief Financial Officer — Lucas G. Montarce Chief Scientific Officer and President, Lilly Immunology — Dan M. Skovronsky, M.D., Ph.D. President, Lilly Neuroscience — Anne E. White President, Lilly International […]
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
Image source: The Motley Fool. Date Wednesday, Oct. 30, 2024 at 10:00 a.m. ET Call participants Chairman and Chief Executive Officer — David A. Ricks Executive Vice President and Chief Financial Officer — Lucas Montarce Chief Scientific and Medical Officer — Daniel M. Skovronsky President, Lilly Diabetes and Obesity — Patrik Jonsson President, Lilly International […]